



About us


Fresenius Medical Care is the world's largest provider of products and services for individuals with renal diseases of which around 3 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,710 dialysis clinics, Fresenius Medical Care provides dialysis treatments for more than 317,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with the core business, the company focuses on expanding the range of related medical services in the field of Care Coordination.

Key figures – 3rd quarter and nine months 2017

		Q3 2017	Growth yoy	9M 2017	Growth yoy
Net revenue	€	4,336 M	3%	13,355 M	10%
Operating income (EBIT)	€	609 M	0%	1,843 M	10%
Net income ¹	€	309 M	2%	886 M	13%
Basic earnings per share	€	1.01	1%	2.89	13%
Net cash provided by operating activities	€	612 M		1,664	
Free cash flow	€	386 M		1,050	
Free cash flow after investing activities	€	330 M		653	
Employees				113,648	

¹ attributable to shareholders of Fresenius Medical Care AG & Co. KGaA


Q3 2017: Revenue per region (in € million)




Q3 2017: Patients, treatments, clinics

	Patients	Treatments (in M)	Clinics
North America	195,027	22.2	2,363
EMEA	61,983	7.0	732
Asia-Pacific	30,151	3.2	389
Latin America	30,631	3.6	230
Total	317,792	36.0	3,714

Basic earnings & dividend per share



Balance sheet (in € million)



Strategy

Our strategy in the coming years will pursue the following four strategic objectives:

- Growing continuously and expanding our global presence
- Tapping into new business areas
- Enhancing products and treatments
- Expanding operational excellence and flexibility

Goals for 2017

Revenue growth	8 to 10 %
Net income growth	7 to 9 %



Geschichte

- September 30, 1996: Foundation of the company
- October 1, 1996: First listing of the shares on the Frankfurt Stock Exchange
- October 2, 1996: First listing of the shares on the New York Stock Exchange
- As of September 20, 1999: Inclusion in the DAX (Deutscher Aktienindex)

Share price – last 12 months (in €)



Basic share data


Ticker Symbols:

Frankfurt Stock Exchange	FME
New York Stock Exchange (NYSE)	FMS
Reuters: XETRA / ADR NYSE:	FMEG.DE/FMS.N
Bloomberg: XETRA / ADR NYSE:	FME GY / FMS US

Security Identification numbers:

WKN	578 580
ISIN	DE 0005785802
CUSIP No. (NYSE)	358029106

Geographical distribution of identified shares



Share capital (as of end of October 2017)

Number of shares outstanding	307,961,563
<i>Fresenius SE & Co. KGaA</i>	30.70%
Free float	~64%
Market capitalization	~25 Bn. €

Ratings

Standard & Poor's	BBB / stable outlook
Moody's	Ba1 / stable outlook
Fitch	BBB- / stable outlook

Management Board

- Rice Powell (Chairman)
- Michael Brosnan (Finance)
- Bill Valle (North America)
- Dr. Olaf Schermeier (Research & Development)
- Kent Wanzek (Production)
- Dominik Wehner (Europe, Middle East, Africa)
- Harry de Wit (Asia-Pacific)

Supervisory Board

- Dr. Gerd Krick (Chairman)
- Dr. Dieter Schenk (Vice Chairman)
- Rolf A. Classon
- William P. Johnston
- Deborah Doyle McWhinney
- Pascale Witz

Financial calendar

Report on the 4th quarter 2017:	February 27, 2018
Report on the 1st quarter 2018:	May 3, 2018
Annual General Meeting:	May 17, 2018
Report on the 2nd quarter 2018:	July 31, 2018
Report on the 3rd quarter 2018:	October 30, 2018

Please note that these dates might be subject to changes.

Contacts

Fresenius Medical Care AG & Co. KGaA
 Investor Relations & Corporate Communications
 Else-Kröner-Str. 1, 61352 Bad Homburg
 Email: ir@fmc-ag.com
Dr. Dominik Heger
 SVP & Head of IR & Corp. Communications
 P: +49(0)6172-609-2525 F: +49(0)6172-609-2301